Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| GHRP-2 | TB-500 (Thymosin Beta-4) | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection. | Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection. |
| Timing | On empty stomach, bedtime administration preferred. Wait 2+ hours after last meal. | No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical. |
| Cycle Duration | 8-16 week cycles. | Loading phase: 4-6 weeks. Total cycle: 8-16 weeks. |
| Evidence Level | moderate_human | animal_plus_anecdotal |
GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide GHS-R1a agonist that is the most potent of the GHRP family for GH release. It stimulates pituitary GH secretion through the ghrelin receptor while also modulating hypothalamic GHRH and somatostatin pathways. GHRP-2 increases GH, cortisol, prolactin, and ACTH release, but with less appetite stimulation than GHRP-6. It also has demonstrated anxiolytic properties and sleep-promoting effects.
Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.
On empty stomach, bedtime administration preferred. Wait 2+ hours after last meal.
8-16 week cycles.
TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino acid protein that sequesters G-actin monomers, preventing premature polymerization and facilitating cellular migration and morphological changes essential for wound healing. It upregulates actin to promote cell migration, proliferation, and differentiation of stem/progenitor cells at injury sites. TB-500 also enhances angiogenesis, reduces inflammation, and promotes tissue remodeling through increased re-epithelialization and vascular density.
Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection.
No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical.
Loading phase: 4-6 weeks. Total cycle: 8-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →